Overview

Clinical Efficacy of Adebrelimab With or Without Apatinib Mesilate and SOX Neoadjuvant Therapy in Locally Advanced Gastric Cancer

Status:
NOT_YET_RECRUITING

Trial end date:
2028-08-25

Target enrollment:

Participant gender:

Summary

Exploring the pathological complete response rate (pCR) of locally advanced gastric cancer treated with adebelimab combined or not combined with apatinib mesylate and SOX neoadjuvant therapy

Phase:

PHASE3

Details

Lead Sponsor:

Fujian Medical University

Treatments:

apatinib